Screener
Avalo Therapeutics AVTX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -36.3%— | -88.8%— | -72.4%-22.4pp | -177.4%-133pp | —— | |
| Return on invested capital | -42.9%— | —— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 19.3×+6.9× | 7.7×-14.9× | 8.1×-11.8× | 14.3×+12.9× | 12.4×+11.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×-0.1× | 0×— | |
| Per Share | ||||||
| Book value per share | $10.29+6.6% | $3.40-70.9% | $6.20-65.1% | $6.54+235% | $9.66+643% | |
| Valuation | ||||||
| Market capitalization | $1B+908% | $340.23M+298% | $329.31M+324% | $167.17M+81.4% | $53.6M+316% | |
| Price / book | 2.2×+1.3× | 5×+4.3× | 4×+3.4× | 1.8×-2.5× | 0.5×— |
FAQ
- What are Avalo Therapeutics's profit margins?
- Avalo Therapeutics (AVTX) runs a 182.0% gross margin and a -15536.1% operating margin, with a -7965.8% net margin.
- Where do Avalo Therapeutics's ratios come from?
- Every ratio is computed from Avalo Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.